BFM
XERS icon

Boothbay Fund Management’s Xeris Biopharma Holdings XERS Stock Holding History

Boothbay Fund Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,710
Closed -$98.9K – 1951
2024
Q3 		$98.9K Hold
34,710
– – ﹤0.01% 1458
2024
Q2 		$78.1K Sell
34,710
-8,490
-20% -$17.1K ﹤0.01% 1375
2024
Q1 		$95.5K Buy
+43,200
New +$112K ﹤0.01% 1425
2022
Q2 		– Sell
-32,414
Closed -$83K – 2717
2022
Q1 		$83K Buy
32,414
+1,984
+7% +$4.85K ﹤0.01% 2126
2021
Q4 		$89K Buy
+30,430
New +$65.7K ﹤0.01% 1729
2020
Q3 		– Sell
-19,190
Closed -$51K – 1247
2020
Q2 		$51K Buy
19,190
+7,390
+63% +$25.7K ﹤0.01% 912
2020
Q1 		$23K Sell
11,800
-1,952
-14% -$8.39K ﹤0.01% 807
2019
Q4 		$97K Buy
+13,752
New +$114K 0.01% 764

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's XERS Position: Q4 2024 in Review

Boothbay Fund Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2024, closing a stake of 34,710 shares — an estimated $98.9K sold.

Boothbay Fund Management first reported a position in XERS in Q4 2019 and held it in 8 quarters. The position peaked at $98.9K in Q3 2024. 162 funds tracked by Wall St. Rank hold XERS as of Q4 2024.

  • Boothbay Fund Management reported no remaining Xeris Biopharma Holdings position as of Q4 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 34,710 Xeris Biopharma Holdings shares in Q4 2024, an estimated $98.9K.
  • Boothbay Fund Management first reported a position in Xeris Biopharma Holdings in Q4 2019 and held it in 8 quarters.
  • Boothbay Fund Management's Xeris Biopharma Holdings position peaked at $98.9K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2024.

Based on Boothbay Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.